Alzheimer’s Drug Study Yields Mixed Results. Wall Street Still Likes Axsome.
In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...
Hosted on MSN4d
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish
Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...
BioSpace1d
Axsome Posts Mixed Phase III Data in Alzheimer’s Agitation, Plans FDA Filing
With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...
STAT4d
Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.
AOL3d
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...
Axsome Therapeutics (NASDAQ:AXSM) Earns “Buy” Rating from Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...
Axsome Therapeutics: Buy Rating Affirmed Amid Promising Trial Outcomes and Path Forward for AXS-05
In a report released yesterday, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $139.75, along ...
Axsome Therapeutics price target raised to $138 from $132 at RBC Capital
RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $138 from $132 and keeps an Outperform rating on the shares after ...
The Pharma Letter3d
Axsome Phase III program of AXS-05 in Alzheimer’s disease agitation
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...
ETF Daily News5d
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Down – Here’s Why
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s stock price gapped down prior to trading on Monday .The stock had previously closed at $86.70, but opened at $82.00. Axsome ...